Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
ADC Therapeutics SA has named Jennifer Herron its first chief commercial officer. Herron recently served as executive vice president and CCO at Immunogen.
Altasciences has named Martin Poirier senior director of bioanalytical sciences. Poirier was formerly scientific director for laboratory sciences at Charles River Laboratories.
Assembly Biosciences has appointed Luisa Stamm chief medical officer. Stamm last served as a senior member of the HCV and HIV clinical research teams with responsibility for scientific and clinical development activities and overall research strategy at Gilead.
Matthew Phillips has been appointed executive vice president of commercial operations at Aytu BioScience. Phillips was formerly chief commercial officer for Cerecor, Inc.
AZTherapies has named Ernest Penachio vice president of manufacturing operations and CMC. Penachio was most recently vice president of manufacturing operations and facilities with Acorda Therapeutics.
BeyondSpring Inc. has named Gregg Russo senior vice president of human resources. Russo previously served as head of human resources at Chugai Pharma USA, a Roche company.
Bruce Steel has been named chief executive officer and Krishna Polu executive vice president of research and development and chief operating officer at Eqillium, Inc. Steel previously served as president and chief business officer; Polu was most recently chief medical officer at the company.
Evoke has named Karsten Risch chief medical officer. Risch was most recently CMO at Havas Health & You.
Flagship Pioneering has appointed Prakash Raman to the newly created role of chief business development officer. Raman was most recently vice president and global head of business development and licensing at Novartis Institutes for BioMedical Research.
Kelly Petrucci has been named vice president of healthcare economics and market access at Gynesonics. Petrucci was previously director of payer relations and value based offers with Boston Scientific.
Jon Zimmerman has been named chief executive officer at Holon Solutions. Zimmerman was previously president of Virence Health.
IDEAYA Biosciences, Inc. has appointed Paul Barsanti vice president and head of drug discovery. Barsanti was most recently an executive in residence at 5AM Ventures.
Kaleido Biosciences, Inc. has expanded its leadership team with the addition of William Duke as chief financial officer. Duke previously served as CFO of Pulmatrix, Inc.
Alfred Reszka has been appointed chief business officer at Lifescience Dynamics. Reszka previously held the position of executive director and head of strategic business intelligence at Merck & Co.
Bill Little has been appointed chief operating officer at Neovasc Inc. Little was most recently global head of customer and new market insights and divisional vice president of global marketing with Abbott.
Neurana Pharmaceuticals Inc. has named Randall Kaye chief medical officer. Kaye was most recently CMO of Click Therapeutics.
Newronika, a neurological research center spinoff from the University of Milan, has named Oleg Svanidze chief medical officer. Svanidze most recently was CMO at Swiss-based Xeltis AG.
Alexander Hunter has been named chief commercial officer at Noxopharm. Hunter’s most recent appointment was chief financial officer at Elk Petroleum.
Shyam Subramanian was named vice president and head of technical operations, Parnian Zia-Amirhosseini vice president and head of regulatory affairs and quality assurance, and Melanie Call vice president and head of program development at Obisidian Therapeutics. Subramanian previously held the position of head of cell therapy development and manufacturing at Casebia Therapeutics. Zia-Amirhosseini most recently served executive director of regulatory affairs at Sarepta Therapeutics. Call previously led the accelerating center at the cell and gene therapy center at IQVIA.
Joseph Fortunak has been named chief scientific officer at OneQor Pharmaceutical. Fortunak is currently a professor of chemistry and pharmaceutical sciences at Howard University.
Partner Therapeutics, Inc. has appointed John McManus chief business officer. McManus was most recently chief executive officer at Aeolus Pharmaceuticals.
Brenton Keath has been appointed chief financial officer and Dana Johnson as general counsel and corporate secretary at Rakuten Medical. Keath previously served as head of finance for Rakuten Commerce in the U.S. Johnson most recently served as vice president and head of legal affairs and corporate compliance for Gritstone Oncology.
Relay Therapeutics has expanded its senior management team with the appointment of Andy Porter as executive vice president and chief people experience officer. Porter was most recently chief people officer at the Broad Institute of MIT and Harvard.
Rubius Therapeutics, Inc. has named Maiken Keson-Brookes chief legal officer and corporate secretary. Keson-Brookes was most recently general counsel at Synlogic, Inc.
Rakesh Verma has been appointed senior vice president of discovery and development at RubrYc Therapeutics, Inc. Prior to the appointment at RubrYc, Verma was site head of ARMO Biosciences.
T1D Exchange has named David Walton chief executive officer. Walton was previously chief commercial officer at QuiO.
Teva Pharmaceutical Industries Ltd. named Eli Kalif as executive vice president and chief financial officer. Kalif was most recently senior vice president of finance at Flex Ltd.
Vericel Corporation has named Sean Flynn vice president and general counsel. Flynn formerly served as vice president and general counsel at Verastem, Inc.